You can find the annual or quarterly income statement of LENZ Therapeutics Inc here for insights into the performance and operational efficiency of LENZ Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q3
FY2020Q2
FY2020Q1
Total revenue
9.72%5.49M
--1.90M
--1.59M
--12.50M
--5.00M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Revenue
9.72%5.49M
--1.90M
--1.59M
--12.50M
--5.00M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Cost of revenue
--280.00K
--1.08M
--418.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating expenses
81.44%39.66M
171.90%46.04M
163.06%40.05M
142.46%31.39M
52.29%21.86M
5.24%16.93M
4.27%15.22M
-5.36%12.95M
-31.54%14.35M
-32.59%16.09M
-45.42%14.60M
-47.70%13.68M
-21.71%20.96M
-8.06%23.87M
41.24%26.75M
79.11%26.15M
52.72%26.78M
177.09%25.96M
--18.94M
287.94%14.60M
1257.04%17.53M
7642.15%9.37M
--3.76M
--1.29M
--121.00K
R&D expenses
-100.00%0.00
-100.00%0.00
-100.00%0.00
-41.23%3.79M
30.47%9.06M
-44.79%5.82M
--5.87M
170.60%6.45M
-48.59%6.95M
-35.13%10.54M
-100.00%0.00
-86.97%2.38M
-24.01%13.51M
-10.97%16.24M
64.77%18.46M
110.78%18.30M
40.34%17.78M
239.33%18.25M
--11.21M
275.89%8.68M
2894.56%12.67M
--5.38M
--2.31M
--423.00K
--0.00
Depreciation, depletion, and amortization
478.95%110.00K
208.33%111.00K
328.00%107.00K
1150.00%125.00K
5.56%19.00K
620.00%36.00K
-82.39%25.00K
-98.75%10.00K
-97.88%18.00K
-99.29%5.00K
-79.71%142.00K
14.29%800.00K
41.50%849.00K
59.09%700.00K
112.12%700.00K
250.00%700.00K
417.24%600.00K
340.00%440.00K
--330.00K
354.55%200.00K
11500.00%116.00K
--100.00K
--44.00K
--1.00K
--0.00
Other operating expenses
----
----
----
----
----
----
----
----
----
----
--1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating profit
-102.72%-34.17M
-160.68%-44.13M
-152.63%-38.46M
-45.90%-18.89M
-17.45%-16.86M
-5.24%-16.93M
-4.27%-15.22M
5.36%-12.95M
31.54%-14.35M
32.59%-16.09M
45.42%-14.60M
47.70%-13.68M
21.71%-20.96M
8.06%-23.87M
-41.24%-26.75M
-79.11%-26.15M
-52.72%-26.78M
-177.09%-25.96M
---18.94M
-287.94%-14.60M
-1257.04%-17.53M
-7642.15%-9.37M
---3.76M
---1.29M
---121.00K
Net non-operating interest income (expenses)
Non-operating interest income
1.07%2.27M
13.82%2.64M
16.37%2.99M
-19.55%2.20M
-8.81%2.25M
194.80%2.32M
--2.57M
--2.74M
--2.46M
--788.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--20.00K
--20.00K
Special income (expenses)
----
----
----
----
----
----
----
----
----
----
---10.95M
---11.35M
---36.90M
---2.58M
----
----
----
----
----
----
----
----
----
----
----
- Gains from disposal of fixed assets
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
---300.00K
---71.00K
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
-106.53%-13.00K
127.27%3.00K
-5312.50%-417.00K
-133.33%-14.00K
-87.83%199.00K
99.18%-11.00K
-89.33%8.00K
98.55%-6.00K
--1.64M
---1.35M
-96.51%75.00K
-128.06%-413.00K
----
----
21420.00%2.15M
14620.00%1.47M
20900.00%840.00K
101.19%123.00K
--10.00K
-97.37%10.00K
--4.00K
---10.34M
--380.00K
--0.00
--0.00
Income before tax
-121.45%-31.91M
-183.80%-41.49M
-183.72%-35.89M
-63.49%-16.70M
-40.55%-14.41M
12.19%-14.62M
44.80%-12.65M
54.57%-10.21M
81.46%-10.25M
30.44%-16.65M
6.83%-22.92M
8.90%-22.48M
-113.27%-55.31M
7.36%-23.93M
-29.95%-24.60M
-69.15%-24.68M
-47.96%-25.94M
-31.08%-25.84M
---18.93M
-331.21%-14.59M
-1236.05%-17.53M
-13878.01%-19.71M
---3.38M
---1.31M
---141.00K
Income tax
-99.40%3.00K
----
100.00%2.00K
--0.00
--500.00K
----
--1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
-114.04%-31.92M
-183.80%-41.49M
-183.74%-35.90M
-63.49%-16.70M
-45.43%-14.91M
12.19%-14.62M
44.80%-12.65M
54.57%-10.21M
81.46%-10.25M
30.44%-16.65M
6.83%-22.92M
8.90%-22.48M
-113.27%-55.31M
7.36%-23.93M
-29.95%-24.60M
-69.15%-24.68M
-47.96%-25.94M
-31.08%-25.84M
---18.93M
-331.21%-14.59M
-1236.05%-17.53M
-13878.01%-19.71M
---3.38M
---1.31M
---141.00K
Net income from continuous operations
-114.04%-31.92M
-183.80%-41.49M
-183.72%-35.90M
-63.49%-16.70M
-45.43%-14.91M
12.19%-14.62M
44.79%-12.65M
54.57%-10.21M
81.46%-10.25M
30.44%-16.65M
6.83%-22.92M
8.90%-22.48M
-113.27%-55.31M
7.36%-23.93M
-29.95%-24.60M
-69.15%-24.68M
-47.96%-25.94M
-31.08%-25.84M
---18.93M
-331.21%-14.59M
-1236.05%-17.53M
-13878.01%-19.71M
---3.38M
---1.31M
---141.00K
Other net gains and losses
----
----
----
----
----
----
---1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
-114.04%-31.92M
-183.80%-41.49M
-183.72%-35.90M
-63.49%-16.70M
-45.43%-14.91M
12.19%-14.62M
44.79%-12.65M
54.57%-10.21M
81.46%-10.25M
30.44%-16.65M
6.83%-22.92M
8.90%-22.48M
-113.27%-55.31M
7.36%-23.93M
-29.95%-24.60M
-69.15%-24.68M
-47.96%-25.94M
-31.08%-25.84M
---18.93M
-331.21%-14.59M
-1236.05%-17.53M
-13878.01%-19.71M
---3.38M
---1.31M
---141.00K
Net income attributable to common shareholders
-114.04%-31.92M
-183.80%-41.49M
-183.72%-35.90M
-63.49%-16.70M
-45.43%-14.91M
12.19%-14.62M
44.79%-12.65M
54.57%-10.21M
81.46%-10.25M
30.44%-16.65M
6.83%-22.92M
8.90%-22.48M
-113.27%-55.31M
7.36%-23.93M
-29.95%-24.60M
-69.15%-24.68M
-47.96%-25.94M
-31.08%-25.84M
---18.93M
-331.21%-14.59M
-1236.05%-17.53M
-13878.01%-19.71M
---3.38M
---1.31M
---141.00K
Basic earnings per share
-91.56%-1.02
-149.16%-1.32
-151.26%-1.15
-55.65%-0.59
-32.63%-0.53
84.95%-0.53
83.44%-0.46
86.32%-0.38
94.13%-0.40
-17.67%-3.53
10.21%-2.77
12.17%-2.75
-105.11%-6.82
10.44%-3.00
-25.17%-3.09
-61.68%-3.13
-51.77%-3.33
-40.97%-3.35
---2.47
-374.55%-1.94
-1286.19%-2.19
-13865.02%-2.38
---0.41
---0.16
---0.02
Diluted earnings per share
-91.56%-1.02
-149.16%-1.32
-151.26%-1.15
-55.65%-0.59
-32.63%-0.53
84.95%-0.53
83.44%-0.46
86.32%-0.38
94.13%-0.40
-17.67%-3.53
10.21%-2.77
12.17%-2.75
-105.11%-6.82
10.44%-3.00
-25.17%-3.09
-61.68%-3.13
-51.77%-3.33
-40.97%-3.35
---2.47
-374.55%-1.94
-1286.19%-2.19
-13865.02%-2.38
---0.41
---0.16
---0.02
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
FAQs
How do I read LENZ Therapeutics Inc's income statement on TradingKey?
Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.
What is the difference between quarterly and annual income statements?
A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.
What does YOY mean on the income statement page?
YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.
Which income statement metrics matter most when analyzing LENZ stock?
Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.
What was LENZ Therapeutics Inc's revenue at year end?
LENZ Therapeutics Inc reported 19.09M in revenue for fiscal year 2025, up from 19.09M in the previous year.
How much revenue did LENZ Therapeutics Inc report in the most recent quarter?
LENZ Therapeutics Inc reported 5.49M in revenue for the most recent quarter, an increase of 9.72% year over year.
What was LENZ Therapeutics Inc's net income for the year?
LENZ Therapeutics Inc posted -82.13M in net income for fiscal year 2025.
How much net income did LENZ Therapeutics Inc post in the last quarter?
LENZ Therapeutics Inc reported -31.92M in net income for the latest quarter。
What was LENZ Therapeutics Inc's annual operating profit?
LENZ Therapeutics Inc's operating income was -91.14M for fiscal year 2025.
How is EPS related to the income statement?
EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.